Capital Research Global Investors Boosts Stock Position in CVS Health Corporation $CVS

Capital Research Global Investors lifted its holdings in shares of CVS Health Corporation (NYSE:CVS) by 5.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 12,043,423 shares of the pharmacy operator’s stock after acquiring an additional 574,173 shares during the period. Capital Research Global Investors’ holdings in CVS Health were worth $955,766,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of CVS. Alteri Wealth LLC boosted its stake in CVS Health by 3.2% in the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after purchasing an additional 131 shares in the last quarter. TOWER TRUST & INVESTMENT Co boosted its stake in CVS Health by 0.8% in the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after purchasing an additional 132 shares in the last quarter. Holistic Financial Partners boosted its stake in CVS Health by 4.1% in the 3rd quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock worth $256,000 after purchasing an additional 133 shares in the last quarter. CYBER HORNET ETFs LLC boosted its stake in CVS Health by 4.1% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after purchasing an additional 134 shares in the last quarter. Finally, LS Investment Advisors LLC boosted its stake in CVS Health by 3.9% in the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after purchasing an additional 135 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently commented on CVS. Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. Barclays lifted their target price on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. The Goldman Sachs Group lifted their target price on shares of CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Piper Sandler reiterated an “overweight” rating and issued a $113.00 target price on shares of CVS Health in a research note on Monday, June 1st. Finally, Morgan Stanley upped their target price on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $99.88.

CVS Health Trading Up 1.4%

Shares of NYSE:CVS opened at $96.11 on Friday. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $98.43. The company has a market capitalization of $122.62 billion, a PE ratio of 42.34, a PEG ratio of 0.94 and a beta of 0.62. The business has a 50 day moving average of $84.13 and a two-hundred day moving average of $80.03. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the company posted $2.25 earnings per share. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s payout ratio is presently 117.18%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to a Zacks Rank #2 (Buy), reflecting improved earnings optimism and adding to the bullish tone around the stock. Article Title
• Positive Sentiment: Broker sentiment remains constructive on CVS Health, with recent coverage pointing to favorable views from Wall Street analysts and broader confidence in the company’s outlook. Article Title
• Positive Sentiment: The managed-care group rallied after analysts cited softer medical cost and utilization trends across the sector, which can support margins and spill over positively to CVS Health. Article Title
• Neutral Sentiment: CVS Health highlighted community and affordable-housing projects in New Jersey and Massachusetts, underscoring its corporate social responsibility efforts, but these announcements are unlikely to move the stock materially. Article Title
• Neutral Sentiment: Media coverage noted CVS Health is up about 8.5% since its last earnings report and asked whether the rally can continue, mainly reflecting investor attention on post-earnings momentum rather than a new catalyst. Article Title
• Neutral Sentiment: CVS CEO comments on AI, “super apps,” and primary care suggest longer-term strategy focus, but there was no immediate financial update in the coverage. Article Title
• Neutral Sentiment: Additional community partnership news, including a job training lab in Lincoln Heights, is supportive of the brand but not a direct earnings driver. Article Title

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.